ZYXI (Zynex Corp) Total Debt to Capital

Public company logo of Zynex Inc (ZYXI)

Zynex, Inc. (ZYXI) dominates the rehabilitation niche through its unique NexWave systems, offering an effective alternative to opioids. Company management ensures strict resource optimization and high direct sales growth rates. This price chart reflects the debt-to-equity ratio, which currently stands at 0.00. Service stability is maintained through streamlined equipment delivery chains and remote user support.

ZYXI: Zynex Debt to Capital 07/04/2022 - 01/03/2026

Analytical breakdowns and data insights for company Zynex Corp (ZYXI)

- stock quotes and analyst forecast:
Stock Quotes Zynex|ZYXI - Analyst Forecast Prices
- business market valuation indicators:
Market Capitalization Zynex|ZYXI - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Zynex|ZYXI - Total Stockholders' Equity|Market Value to Book Value Ratio zynex.com|ZYXI - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Capital Zynex, Inc.|ZYXI - Long-Term Debt to Capital|Short-Term Debt to Equity Zynex, Inc.|ZYXI - Company Aggregate Indebtedness|Debts to Book Capitalization Zynex|ZYXI - Long-Term Debt|Company Current Liabilities Zynex|Quick Liquidity Indicator zynex.com
- earnings and valuation multiples information:
ZYXI - Profit After Payment of Taxes
Summary company analytics:Zynex, ZYXI
Finished products of Zynex, Inc.

Zynex, Inc. occupies a stable niche in the medtech sector, leveraging an optimized equipment distribution system via internal warehouse hubs. An analysis of the D/E ratio (total debt to equity) allows for an assessment of the proportion of borrowed funds to equity assets, where a decrease in this metric indicates deleveraging and increased financial autonomy, fundamentally strengthening the business's resilience to market shocks.

Competitors of Zynex, Inc.

Total Debt to Equity Ratio DXCM|PEN (Penumbra Inc) - Aggregate Debt to Capital|Total Debt to Capital NOVT|HAE (Haemonetics Company) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital INSP (Inspire Medical Systems)|procept-biorobotics.com (PRCT) - Debt to Capital|CNMD - Debt to Equity|All Debt to Shareholders' Equity Ratio PLSE (Pulse Biosciences Inc)|INMD: Total Debt to Capital|Picard Group (PMI) - Total Debt to Capital|Debt to Equity Surmodics, Inc.|Senseonics Corp - Aggregate Debt to Equity|Total Debt to Capital NPCE|TCMD - Debt to Capital|SANUWAVE Health, Inc. - Total Debt to Equity Ratio|Total Debt to Capital Outset Medical Corp OM|ELMD: Total Debt to Equity Ratio|lensar.com - Aggregate Debt to Capital|RCEL: Total Debt to Capital|PROF - Total Debt to Capital Coefficient|BDMD (Baird Medical Investment Holdings) - Total Debt to Capital|Total Debt to Equity Ratio EDAP Medical (EDAP)|Total Debt to Equity Ratio APYX (Apyx Medical)|ICCM (icecure-medical.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Pulmonx LUNG|TELA - Total Debt to Equity Ratio|CytoSorbents Corp. - Total Debt to Capital|Debt to Capital Sensus|ECOR: Total Debt to Capital|Debt to Equity Ratio RBOT|IINN (Inspira Technologies Oxy B.H.N. Ltd.) - Total Debt to Capital|SeaStar Medical Holding Corporation (ICU) - Total Debt to Capital Coefficient|Total Debt to Capital IRIX|Total Debt to Equity Ratio ibs.inc INBS|Total Debt to Capital XAIR (Beyond Air)|Total Debt to Capital profusa.com PFSA|SSKN - Debt to Equity|GCTK: Debt to Equity|NAOV (NanoVibronix) - Total Debt to Equity Ratio|Venus Concept Corporation - All Debt to Shareholders' Equity Ratio|NUWE (Nuwellis, Inc.) - Total Debt to Capital|Debt to Capital aethlonmedical.com AEMD|Debt to Equity Asensus Surgical, Inc. (ASXC)|Avinger Inc. (AVGR) - Debt to Capital Ratio|BioSig Technologies, Inc. - Total Debt to Equity Ratio|Total Debt to Capital Cutera Inc CUTR|Know Labs, Inc. - Total Debt to Capital|Total Debt to Capital Coefficient inarimedical.com NARI|Nevro (NVRO) - Debt to Equity|Aggregate Debt to Equity RSLS (ReShape Lifesciences Inc.)|Debt to Equity Silk Road Medical Inc.